|ECHA InfoCard||Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).|
|Molar mass||625.749 g/mol|
|Except where noted otherwise, data are given for|
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references
Rhizoxin is biosynthesised by Burkholderia rhizoxina, an endosymbiotic bacteria of the fungus Rhizopus microsporus. It is one of a large group of rhizoxin-like compounds produced by the bacteria. The bacterial endosymbiote can be grown independently in culture. This may allow easy harvesting of rhizoxin and the related compounds avoiding total chemical synthesis, although total chemical synthesis is possible.
Rhizoxin binds beta tubulin in eukaryotic cells disrupting microtubule formation. This, in turn, prevents formation of the mitotic spindle inhibiting cell division. Additionally rhizoxin can depolymerise assembled microtubules. The function of rhizoxin is similar to Vinca alkaloids.
Rhizoxin has undergone clinical trials as an anti-cancer drug although, unfortunately, did not reach later stages of clinical trials due to low activity in vivo. Related compounds to rhizoxin may have improved biological activity.
- Tsuro, T., et al., "Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine resistant sublines". Cancer Res., 46, 381-385 (1986).
- Ikubo, S., et al., "In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines". Anticancer Res., 19, 3985-3988 (1999).
- Laila, P., et al., "Pathogenic fungus harbours endosymbiotic bacteria for toxin production"., Nature 437, 884-888., (2005).
- Scherlach, K., et al., "Antimitotic Rhizoxin Derivatives from a Cultured Bacterial Endosymbiont of the Rice Pathogenic Fungus Rhizopus microsporus". J. Am. Chem. Soc. 128 (35) 11529 - 11536., (2006).
- Mitchell, I.S., et al., "A total synthesis of the antitumour macrolide rhizoxin D". Org. Biomol. Chem. 24 4412-31 (2005).
- Takahashi, M., et al., "Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues." J. Antibiot. (Tokyo)., 40 (1), 66-72. (1987). Erratum in J. Antibiot. (Tokyo)., 40 (4), following 565. (1987).
- McLeod, H.L., et al., "Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups"., Br. J. Cancer. 74 (12) 1944-8., (1996).
- Iwasaki, S., et al., "Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis." J. Antibiot. (Tokyo). 37 (4), 354-62 (1984).